Cyclopharm Limited ( (AU:CYC) ) has issued an update.
Cyclopharm Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO James McBrayer will present. This engagement highlights Cyclopharm’s ongoing efforts to engage with stakeholders and showcase its advancements in nuclear medicine, potentially enhancing its industry positioning and stakeholder relations.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community. The company focuses on improving patient care outcomes through its core product, Technegas, which is used in functional lung ventilation imaging. Technegas technology involves a dispersion of radioactive-labelled carbon for evaluating functional ventilation imaging, historically used for diagnosing pulmonary embolism and now applied to other conditions such as COPD, asthma, and pulmonary hypertension.
YTD Price Performance: -9.49%
Average Trading Volume: 161,063
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$162.3M
See more insights into CYC stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com